Rephonic
Artwork for BioCentury This Week

BioCentury This Week

BioCentury
FDA
China
Biotech
Biotechnology
Clinical Trials
Biosecure Act
Biotech Industry
Obesity
Alzheimer's Disease
Mergers and Acquisitions
Drug Development
Psychedelics
Gene Therapy
FDA Regulations
Novo Nordisk
Inflation Reduction Act
Biotech Innovation
Pediatric Priority Review Vouchers
Biotech Ipos
Biopharma

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

PublishesWeeklyEpisodes408Founded7 years ago
Number of ListenersCategories
Life SciencesBusinessScience

Listen to this Podcast

Artwork for BioCentury This Week

Latest Episodes

J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts d... more

YouTube

Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipartisan drug pricing legislation. On the latest BioCentury This Week podcast, BioCentury’s analysts asse... more

YouTube

Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th B... more

YouTube

A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discu... more

YouTube

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Recent Guests

Weihao Xu
Founder and CEO of Kali Therapeutics
Kali Therapeutics
Episode: Ep. 396 - China’s first-order innovation
Matthew Hewitt
VP and CTO of the Manufacturing Business Unit at Charles River
Charles River
Episode: Ep. 396 - China’s first-order innovation
Jack O'Meara
Co-founder and CEO of Aerska
Aerska
Episode: Ep. 396 - China’s first-order innovation
Dinko Valerio
Co-founder and chairman of Leyden Labs
Leyden Labs
Episode: Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
Lauren Martz
Executive editor covering product development
BioCentury
Episode: Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
Mike Davis
CDER director (interim/appointed)
FDA/CDER
Episode: Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Nick Galakatos
Executive at Blackstone Life Sciences
Blackstone Life Sciences
Episode: Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Peter Barton Hutt
FDA law icon, former chief counsel at FDA
Episode: Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Heidi Overton
Nominee for FDA commissioner
Public health / FDA nominee
Episode: Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Hosts

Stephen Hansen
BioCentury editor and industry observer with UK coverage.
Jeff Cranmer
Host with broad coverage in biotech policy and market dynamics.
Jeff Kranmer
Host focused on market updates and deal analysis.
Simone Fishburne
Editor-in-Chief offering editorial and policy context.

Reviews

4.7 out of 5 stars from 80 ratings
  • terrific summaries capturing the news in this fast-moving space

    LOVE this weekly look at what is happening in biotech, both deep dives into the science itself plus the regulatory/legislative challenges and more. All the regulars are deeply knowledgeable and Jeff Cranmer’s levity as host makes the pod enjoyable and digestible--you really do feel like you have a seat at their editorial meetings. GREAT recaps of the news and in ~30 min or less, I look forward to listening each week!

    Apple Podcasts
    5
    Ios9 problem
    United States2 years ago
  • Great insights and wisdom!

    Awesome helps me and my team navigate efficiently

    Apple Podcasts
    5
    Surfrider182
    United States2 years ago
  • Simone Fishburn!!!!

    Simone Fishburn is so well spoken and such a tremendous host. Need more of her in our lives !!

    Apple Podcasts
    5
    Pretty Kitty 2
    United States6 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Simone Fishburne is repeatedly praised for clear, strong editorial leadership.
Listeners appreciate concise, digestible summaries of fast-moving biotech news.
The host brings levity and clarity, making complex topics approachable.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Ep. 395 - ESMO analysis & Auchincloss proposal
Q: What is in Representative Jake Auchincloss' Faster Clinical Trials Act, and how important is it?
The bill would embed trials in routine care, establish networks for reusable clinical trial platforms, streamline some early-stage trial processes, give foreign clinical data equal consideration, and expand the All of Us biobank. Usden said it could significantly affect U.S. drug development, though funding and legislative support remain challenges.
Ep. 395 - ESMO analysis & Auchincloss proposal
Q: What did you find in your analysis of the first-in-human trials presented at ESMO?
The review of about 70 abstracts found that ADCs outnumbered other modalities, with substantial innovation in tumor targets but limited diversity in payloads. Martz also highlighted first-in-class potential and varied bispecific antibody formats.
Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
Q: What is the most important factor when bridging academia and industry?
Understanding and teaching entrepreneurship to scientists, selecting the right teams, and forming the networks that connect scientific founders with investors early, so that scientists learn how to meet the money and build durable companies.
Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
Q: How do you see Europe catching up with the US in biotech funding and infrastructure?
There's a move to accelerate funding from national pots and European commissions, and to build a home-grown ecosystem with the right talent, infrastructure, and leadership to keep companies from relocating to Boston; collaboration with US investors is rising, and it's about building a sustainable European platform.
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Q: What is the FDA's stance on 12-week efficacy data and preliminary long-term follow-up for psychedelic therapies?
The panel notes that the final guidance sets a 12-week assessment as a baseline, but leaves the exact definition of preliminary follow-up to program-specific negotiations, meaning sponsors must argue why their data meets the agency's evidentiary standards.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About BioCentury This Week

What is BioCentury This Week about and what kind of topics does it cover?

Biotech-focused analysis and updates, with a steady cadence of market context, policy shifts, and deal-making intersecting with science progress. Episodes frequently dissect FDA timelines, regulatory reforms, and cross-border regulatory dynamics, then pair that with deep dives into therapeutic modalities (ADCs, DACs, CAR-T, gene therapies) and notable clinical readouts from major conferences. Guests range from editors and policy reporters to executives, analysts, and scientists, yielding practical takeaways for sponsors, investors, and operators. A distinctive feature is the blend of rigorous industry data with accessible host commentary and a recurring emphasis on translating science and policy into business strategy. This mix makes it use... more

Where can I find podcast stats for BioCentury This Week?

Rephonic provides a wide range of podcast stats for BioCentury This Week. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to BioCentury This Week and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does BioCentury This Week get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for BioCentury This Week, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for BioCentury This Week?

Rephonic provides comprehensive predictive audience data for BioCentury This Week, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does BioCentury This Week have?

To see how many followers or subscribers BioCentury This Week has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to BioCentury This Week?

These podcasts share a similar audience with BioCentury This Week:

1. Biotech Hangout
2. The Readout Loud
3. The Long Run with Luke Timmerman
4. The BioCentury Show
5. Business Of Biotech

How many episodes of BioCentury This Week are there?

BioCentury This Week launched 7 years ago and published 408 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact BioCentury This Week?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for BioCentury This Week?

Rephonic pulls ratings and reviews for BioCentury This Week from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for BioCentury This Week?

Rephonic provides full transcripts for episodes of BioCentury This Week. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on BioCentury This Week?

Recent guests on BioCentury This Week include:

1. Weihao Xu
2. Matthew Hewitt
3. Jack O'Meara
4. Dinko Valerio
5. Lauren Martz
6. Mike Davis
7. Nick Galakatos
8. Peter Barton Hutt

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days